Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis.

Clinical and translational science - 1 Apr 2023

Anderson Justin D, Davis Brittney H, Giang Gracie, Jones April, Lee Cameron R, Parker Kennedy, Searcy Heather, Benner Kim, Limdi Nita A, Guimbellot Jennifer S

Abstract excerpt

Although major advancements have been made in the therapeutics for people with cystic fibrosis (PwCF), many still require the use of multiple medications to manage acute exacerbations of disease and maintain health. Iterative trial and error processes of pharmacotherapeutic management can be optimized by assessing and incorporating pharmacogenetics. For 82 PwCF, we reviewed 2 years of medication use and response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Child Nutrition and Feeding Issues

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Research Advances

Share to Genotype

Share to Pharmaceutical studies and practices

Share to Pharmacogenetics

Source

Open in PubMed Open full text

Identifiers

PMID: 36760155
DOI: 10.1111/cts.13479
PMCID: PMC10087076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis.PMID 36760155Read ↗

Opportunity for pharmacogenomic testing in patients with cystic fibrosis.Semantic proximity Read ↗

Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis.Semantic proximity Read ↗

Pharmacogenetics and Theratyping in Pulmonology: A Practical GuideSemantic proximity Read ↗

Genotype-predicted drug response phenotypes and their co-occurrence with dispensed medicines among 738,531 participants in the UK Our Future Health studySemantic proximity Read ↗

Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort studySemantic proximity Read ↗

Critically Ill Children Frequently Receive Medications with Established but Unused Pharmacogenomic Guidelines: Actionable Findings from an Integrated Electronic Medical Record and Exome Sequencing StudySemantic proximity Read ↗

Pharmacogenomics in general practice: The time has comeSemantic proximity Read ↗

Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.Semantic proximity Read ↗

Evaluating genotype-treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank.Semantic proximity Read ↗

Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community-Dwelling Older Adults.Semantic proximity Read ↗

Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.Semantic proximity Read ↗

Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.